Guarneri, V., Dieci, M. V., Frassoldati, A., Maiorana, A., Ficarra, G., Bettelli, S., Tagliafico, E., Bicciato, S., Generali, D. G., Cagossi, K., Bisagni, G., Sarti, S., Musolino, A., Ellis, C., Crescenzo, R., & Conte, P. (2015). prospective Biomarker Analysis of the Randomized CHER‐LOB Study Evaluating the Dual Anti‐HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2‐Positive Breast Cancer. Oncologist, 20, 1001–1010. http://access.bl.uk/ark:/81055/vdc_100054355926.0x000033